$GKOS

Thurman Alex R. sold $3.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 20,000 shares of GLAUKOS Corp (GKOS) at $180.13 ($3.60M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Aug 11, 2026, 9:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest disclosed fact is the Aug 7 open-market sale of 20,000 shares by the CFO, filed Aug 11, with holdings after the sale of 43,906 shares.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying operational or financial news.

03

What to watch

The filing does not disclose reasons for the sale, and the presence of a pre-arranged plan often limits interpretability for traders.

Relevance 5/10Novelty 3/10Timing: filed Aug 11, transaction dated Aug 7

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos (GKOS).

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos CFO Thurman Alex sold 20,000 shares in an open-market transaction for about $3.6M under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless paired with other news.

Evidence & confidence

Form 4 details an open-market sale by an officer with a stated 10b5-1 plan, which typically reduces signaling value versus discretionary selling.

Market effects

Minimal; insider-sale Form 4s rarely change sector fundamentals.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification or tax planning under the 10b5-1 plan, so it may not reflect bearish expectations.

Key entities

  • GLAUKOS Corp

    Company whose insider transaction is disclosed on Form 4.

  • Thurman Alex R.

    SVP and Chief Financial Officer who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.